Amyloid fiber formation

D'Eustachio, P., Jassal, B., Jupe, S., Meras-Rios, A., Perry, G.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 International (CC BY 4.0) License. For more information see our license.

This is just an excerpt of a full-length report for this pathway. To access the complete report, please download it at the Reactome Textbook.

28/12/2022
Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references


Reactome database release: 83

This document contains 1 pathway and 33 reactions (see Table of Contents)
Amyloid is a term used to describe deposits of fibrillar proteins, typically extracellular. The abnormal accumulation of amyloid, amyloidosis, is a term associated with tissue damage caused by amyloid deposition, seen in numerous diseases including neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's. Amyloid deposits consist predominantly of amyloid fibrils, rigid, non-branching structures that form ordered assemblies, characteristically with a cross beta-sheet structure where the sheets run parallel to the direction of the fibril (Sawaya et al. 2007). Often the fibril has a left-handed twist (Nelson & Eisenberg 2006). At least 27 human proteins form amyloid fibrils (Sipe et al. 2010). Many of these proteins have non-pathological functions; the trigger that leads to abnormal aggregations differs between proteins and is not well understood but in many cases the peptides are abnormal fragments or mutant forms arising from polymorphisms, suggesting that the initial event may be aggregation of misfolded or unfolded peptides. Early studies of Amyloid-beta assembly led to a widely accepted model that assembly was a nucleation-dependent polymerization reaction (Teplow 1998) but it is now understood to be more complex, with multiple 'off-pathway' events leading to a variety of oligomeric structures in addition to fibrils (Roychaudhuri et al. 2008), though it is unclear whether these intermediate steps are required in vivo. An increasing body of evidence suggests that these oligomeric forms are primarily responsible for the neurotoxic effects of Amyloid-beta (Roychaudhuri et al. 2008), alpha-synuclein (Winner et al. 2011) and tau (Dance & Strobel 2009, Meraz-Rios et al. 2010). Amyloid oligomers are believed to have a common structural motif that is independent of the protein involved and not present in fibrils (Kayed et al. 2003). Conformation dependent, aggregation specific antibodies suggest that there are 3 general classes of amyloid oligomer structures (Glabe 2009) including annular structures which may be responsible for the widely reported membrane permeabilization effect of amyloid oligomers. Toxicity of amyloid oligomers preceeds the appearance of plaques in mouse models (Ferretti et al. 2011).

Fibrils are often associated with other molecules, notably heparan sulfate proteoglycans and Serum
Amyloid P-component, which are universally associated and seem to stabilize fibrils, possibly by protecting them from degradation.

**Literature references**

Seven in absentia homolog 1 (SIAH1) and 2 (SIAH2) are E3 ubiquitin-protein ligases that mediate ubiquitination of a number of target proteins including Synphilin-1 (SNCAIP) (Nagano et al. 2003) and alpha-synuclein (Liani et al. 2004). They are inhibited by the 1A isoform of SNCAIP (Szargel et al. 2009). When ubiquitinated by SIAH1, SNCAIP is targeted for proteasomal degradation (Nagano et al. 2003).

Synphilin-1 (SNCAIP) is a presynaptic protein that associates with synaptic vesicles (Ribeiro et al. 2002). It is present in many types of cytoplasmic inclusions, where it colocalizes with alpha-synuclein. It is associated with Parkinson's Disease (PD) because it is an intrinsic component of Lewy bodies (Wakabayashi et al. 2000) and a mutation of the SNCAIP gene has been identified in some PD patients (Marx et al. 2003), suggesting that accumulation of synphilin-1 and its interaction with alpha-synuclein may be relevant for Lewy body formation in PD.

Synphilin-1 (SNCAIP) is ubiquitinated by several other E3 ubiquitin-ligases, including Parkin (Chung et al. 2001) and Dorfin (Ito et al. 2003).

Followed by: SIAH1, SIAH2 ubiquitinate SNCAIP

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014-12-17</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-04</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Seven in absentia homolog (SIAH1) and 2 (SIAH2) are E3 ubiquitin-protein ligases that mediate ubiquitination of a number of target proteins including Synphilin-1 (SNCAIP) (Nagano et al. 2003, Liani et al. 2004). When ubiquitinated by SIAH1, SNCAIP is targeted for proteasomal degradation (Nagano et al. 2003). SIAH1 and SIAH2 are inhibited by the 1A isoform of SNCAIP (Szargel et al. 2009). SIAH1 can bind the brain-enriched E2 ubiquitin-conjugating enzyme UBE2L6 (Lee et al. 2008) but the E2 involved in SNCAIP ubiquitination has not been established.

Synphilin-1 (SNCAIP) is a presynaptic protein that associates with synaptic vesicles (Ribeiro et al. 2002). It is present in many types of cytoplasmic inclusions, where it colocalizes with alpha-synuclein. It is associated with Parkinson's Disease (PD) because it is an intrinsic component of Lewy bodies (Wakabayashi et al. 2000) and a mutation of the SNCAIP gene has been identified in some PD patients (Marx et al. 2003), suggesting that accumulation of synphilin-1 and its interaction with alpha-synuclein may be relevant for Lewy body formation in PD.

Synphilin-1 (SNCAIP) is ubiquitinated by several other E3 ubiquitin-ligases, including Parkin (Chung et al. 2001) and Dorfin (Ito et al. 2003).

Preceded by: SIAH1, SIAH2 bind SNCAIP

Literature references


<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-01-23</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-04</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Synphilin-1 (SNCAIP) is a presynaptic protein that associates with synaptic vesicles (Ribeiro et al. 2002). It is present in many types of cytoplasmic inclusions, where it colocalizes with alpha-synuclein (SNCA). It is associated with Parkinson's Disease (PD) because it is an intrinsic component of Lewy bodies (Wakabayashi et al. 2000) and a mutation of the SNCAIP gene has been identified in some PD patients (Marx et al. 2003), suggesting that accumulation of SNCAIP and its interaction with SNCA may be relevant for Lewy body formation in PD.

SNCAIP is ubiquitinated by several different E3 ubiquitin-ligases, including Parkin (PARK2). PARK2 overexpression with SNCAIP in cell culture leads to the formation of protein aggregates (Chung et al. 2001). PARK2 preferentially mediates the addition of lysine-63 (K63)-linked polyubiquitination of SNCAIP (Lim et al. 2005). This leads to SNCAIP degradation only at an unusually high PARK2 to SNCAIP ratio (Lim et al. 2005). K63-linked ubiquitination may be a signal that leads to the degradation of inclusions by autophagy when the ubiquitin-proteasome system is dysfunctional (Lin et al. 2005, Tan et al. 2008).

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014-12-19</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-04</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
SNCAIP is ubiquitinated by several different E3 ubiquitin-ligases, including Parkin (PARK2). PARK2 over-expression with SNCAIP in cell culture leads to the formation of protein aggregates (Chung et al. 2001). PARK2 preferentially mediates the addition of lysine-63 (K63)-linked polyubiquitination of SNCAIP (Lim et al. 2005). This leads to SNCAIP degradation only at an unusually high PARK2 to SNCAIP ratio (Lim et al. 2005). K63-linked ubiquitination may be a signal that leads to the degradation of inclusions by autophagy when the ubiquitin-proteasome system is dysfunctional (Lim et al. 2005, Tan et al. 2008).

**Literature references**

Seven in absentia homolog 1 (SIAH1) and 2 (SIAH2) are E3 ubiquitin-protein ligases that mediates ubiquitination of a number of target proteins including Synphilin-1 (SNCAIP) (Nagano et al. 2003) and alpha-synuclein (SNCA) (Liani et al. 2004, Lee et al. 2008). Ubiquitination of SNCA by SIAH1 is disrupted by the Parkinson's Disease (PD)-linked A30P mutation but not by the A53T mutation. SIAH1 binds the E2 ubiquitin-conjugating enzyme UBE2L6 (UBCH8) (Lee et al. 2008). This facilitates the mono- and di-ubiquitination of SNCA in vivo, but does not target SNCA for proteasomal degradation, rather it promotes SNCA aggregation and enhances toxicity (Lee et al. 2008). Monoubiquitinated SNCA may work as a seed for aggregation (Engelender 2008) and recruit other PD-related proteins, such as SNCAIP and UCHL1.

Followed by: SIAH1:UBE2L6:Ubiquitin ubiquitinates SNCA

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014-12-19</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-04</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
SIAH1 transfers ubiquitin from UBE2L6 to SNCA, generating monoubiquitinated SNCA (Ub-SNCA) (Liani et al 2004, Rott et al. 2008, Lee et al. 2008). Monoubiquitination of SNCA promotes its aggregation in vitro and in vivo, which is toxic to cells. Lewy Bodies, a characteristic of Parkinson's Disease, contain monoubiquitinted SNCA deposits (Hasegawa et al. 2002). Mass spectrometry analysis demonstrates that SIAH monoubiquitinates alpha-synuclein at lysines 12, 21, and 23 (Rott et al. 2008).

Monoubiquitination is generally thought to lead to degradation via the lysosomal pathway (d'Azzo et al. 2005) but monoubiquitinated SNCA appears to be preferentially targeted for degradation by the proteasome (Rott et al. 2011).

**Preceded by:** SIAH1:UBE2L6:Ubiquitin binds SNCA

**Followed by:** Ub-SNCA dissociates from the conjugating enzyme

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-01-06</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-04</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>

https://reactome.org
Ub-SNCA dissociates from the conjugating enzyme

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-5660757

**Type:** uncertain

**Compartments:** cytosol

SNCA is monoubiquitinated and under some circumstances released to accumulate in the cell. Alternatively, Ub-SNCA may undergo further rounds of ubiquitination producing diubiquitinated or polyubiquitinated forms. The precise mechanism of release and subsequent further ubiquitination is unclear (Sadowski et al. 2011); the E3 ligase may remain bound to SNCA while the E2 ligase dissociates to be replaced by a Ubiquitin-associated replacement, or the E2/E3 complex may dissociate completely allowing a different E3 to bind the SNCA substrate.

**Preceded by:** SIAH1:UBE2L6:Ubiquitin ubiquitinates SNCA

**Followed by:** USP9X binds Ub-SNCA

**Literature references**


The deubiquitinase USP9X binds and deubiquitinates alpha-synuclein (SNCA) in vitro and in vivo, showing co-accumulation with SNCA in Lewy Bodies. Knockdown of USP9X expression in conditions of proteolytic inhibition leads to the accumulation of monoubiquitinated SNCA and increases the aggregation of SNCA into toxic inclusions, strengthening the connection between monoubiquitination, inclusion formation, and toxicity of SNCA. USP9X cytosolic levels are lower in Diffuse Lewy Body disease and Parkinson's Disease tissues, which may contribute to the accumulation and aggregation of monoubiquitinated SNCA (Rott et al. 2011).

**Preceded by:** Ub-SNCA dissociates from the conjugating enzyme

**Followed by:** USP9X deubiquitinates Ub-SNCA

**Literature references**

USP9X deubiquitinates Ub-SNCA

Location: Amyloid fiber formation

Stable identifier: R-HSA-5660752

Type: transition

Compartments: cytosol

The deubiquitinase USP9X binds and deubiquitinates alpha-synuclein (SNCA) in vitro and in vivo, showing co-accumulation with SNCA in Lewy Bodies. Knockdown of USP9X expression in conditions of proteolytic inhibition leads to the accumulation of monoubiquitinated SNCA and increases the aggregation of SNCA into toxic inclusions, strengthening the connection between monoubiquitination, inclusion formation, and toxicity of SNCA. USP9X cytosolic levels are lower in Diffuse Lewy Body disease and Parkinson's Disease tissues, which may contribute to the accumulation and aggregation of monoubiquitinated SNCA (Rott et al. 2011).

Preceded by: USP9X binds Ub-SNCA

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-01-06</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-04</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
**USP9X:SNCA dissociates**

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-5661161

**Type:** dissociation

**Compartments:** cytosol

Following the removal of ubiquitin, SNCA is released by USP9X (Rott et al. 2011).

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-01-09</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-04</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
**SNCAIP binds alpha-synuclein**

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-5658104

**Type:** binding

**Compartments:** cytosol

Synphilin-1 (SNCAIP) binds alpha-synuclein (SNCAs) in vivo, which promotes the formation of Lewy body-like inclusions that are characteristic of Parkinson's Disease (Engelender et al. 1999, Kawamata et al. 2001). SNCAIP and PARK2 (Parkin) are found in the central core of a majority of Lewy Bodies in Parkinson's disease (Bandopadhyay et al. 2005).

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014-12-17</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-04</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Serum amyloid P-component forms homopentamers

Location: Amyloid fiber formation

Stable identifier: R-HSA-976723

Type: binding

Compartments: extracellular region

Serum amyloid P component (SAP) is a member of the pentraxin family, characterized by the formation of pentameric ring structures. Each member of the ring has two associated calcium ions. SAP is an acute phase reactant, highly induced by IL-6. It has 50% homology with the related C-reactive peptide.

Followed by: Formation of serum amyloid P decamer, Amyloid fibrils have additional components, Serum amyloid P binds DNA and chromatin

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010-10-15</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
**NAT8,8B acetylate BACE1**

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-5693001

**Type:** transition

**Compartments:** endoplasmic reticulum membrane, endoplasmic reticulum lumen

N-acetyltransferase 8 and 8B (NAT8, 8B) can mediate the molecular stabilisation of BACE1, the membrane protein that acts as the rate-limiting enzyme in the generation of the Alzheimer disease amyloid beta-peptide. Specifically, nascent BACE1 is transiently acetylated on seven lysine residues in the ER lumen which protects the nascent protein from degradation in the ER Golgi intermediate compartment (ERGIC) and allows it to reach the Golgi apparatus (Ko & Puglielli 2009, Costantini et al. 2007). Lysine-acetylated BACE1 (7K-BACE1) is deacetylated in the Golgi apparatus.

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author/Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-05-13</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Beta secretase 1 (BACE1) is acetylated on 7 lysine residues in the ER lumen (7K-BACE1). This protects the nascent protein from degradation in the ER Golgi intermediate compartment (ERGIC) and allows it to reach the Golgi apparatus (Kandalepas & Vassar 2014). The mechanism of this translocation is unknown.

**Followed by:** FURIN cleaves 7K-BACE1 to 7K-BACE1(46-501)

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Author/Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-05-13</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
FURIN cleaves 7K-BACE1 to 7K-BACE1(46-501)

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-5693081

**Type:** omitted

**Compartments:** Golgi membrane, Golgi-associated vesicle lumen

FURIN is the most likely endopeptidase that cleaves the BACE propeptide domain (BACE1(22-45)) to form the mature enzyme (7K-BACE1(46-501)). Although the pro-enzyme possesses proteolytic activity, this activity is approximately doubled following removal of the prodomain (Bennett et al. 2000).

**Preceded by:** BACE1 translocates from ER lumen to Golgi apparatus

**Followed by:** Unknown deacetylase deacetylates 7K-BACE1(46-501)

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-05-13</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Unknown deacetylase deacetylates 7K-BACE1(46-501)

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-5693092

**Type:** omitted

**Compartments:** Golgi-associated vesicle lumen

Mature beta secretase 1, acetylated on 7 lysine residues (7K-BACE1(46-501)), is deacetylated by an unknown deacetylase in the Golgi apparatus (Kandalepas & Vassar 2014).

**Preceded by:** FURIN cleaves 7K-BACE1 to 7K-BACE1(46-501)

**Followed by:** BACE1(46-501) translocates from Golgi lumen to plasma membrane

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Author/Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-05-13</td>
<td>Authored, Edited</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
</tr>
</tbody>
</table>
BACE1(46-501) translocates from Golgi lumen to plasma membrane

Location: Amyloid fiber formation

Stable identifier: R-HSA-5693086

Type: omitted

Compartments: plasma membrane, Golgi-associated vesicle lumen

BACE1(46-501) translocates from the Golgi lumen to the plasma membrane (Walter et al. 2001).

Preceded by: Unknown deacetylase deacetylates 7K-BACE1(46-501)

Followed by: BACE1 binds GGA1,2,3

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-05-13</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
BACE1 binds GGA1,2,3

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-5692934

**Type:** binding

**Compartments:** endosome membrane, plasma membrane

Beta-secretase 1 (BACE1, memapsin-2) mediates the proteolytic processing of amyloid precursor protein (APP). BACE1 is transported from the plasma membrane to endosomes where APP hydrolysis takes place. The acid-cluster-dileucine (ACDL) motif in the cytosolic domain of BACE1 is able to bind to the VHS domain of ADP-ribosylation factor-binding proteins 1, 2 and 3 (GGA1,2,3) which play a role in protein sorting and trafficking between the trans-Golgi network (TGN) and endosomes. This is the presumed recognition step for BACE1 transport to endosomes (He et al. 2003).

**Preceded by:** BACE1(46-501) translocates from Golgi lumen to plasma membrane

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-05-13</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Beta-secretase 1 (BACE1, memapsin-2) mediates the proteolytic processing of amyloid precursor protein (APP). BACE1 is transported from the cell surface to endosomes where APP hydrolysis takes place. The acid-cluster-dileucine (ACDL) motif in the cytosolic domain of BACE1 is able to bind to the VHS domain of ADP-ribosylation factor-binding proteins 1, 2 and 3 (GGA1,2,3) which play a role in protein sorting and trafficking between the trans-Golgi network (TGN) and endosomes. This is the presumed recognition step for BACE1 transport to endosomes (He et al. 2003).

**Followed by:** BACE1 cleaves APP(18-770) to APP(18-671) and APP(672-770)

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-05-13</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Amyloid precursor protein (APP(18-770)) is processed by one of two distinct proteolytic pathways; the non-amyloidogenic pathway where alpha-secretase cleaves APP at the cell surface within the A-beta domain, liberating APPs-alpha and the amyloidogenic pathway, where beta-secretase followed by gamma-secretase cleavages results in peptides which are the main fibril-forming peptides implicated in Alzheimer's disease. In the first step of the amyloidogenic pathway, the endosomal membrane protein beta-secretase 1 (BACE1) catalyses the cleavage of APP(18-770) within the ectodomain and liberates a soluble proteolytic fragment, termed soluble APP-beta (APPs-beta, APP(18-671)) and C99 (APP(672-770)) (Baranello et al. 2015, Andrew et al. 2016). APP processing can occur in several endocytic and secretory pathways. For simplicity, the endosome has been chosen in this event.

**Preceded by:** BACE1:GGA1,2,3 translocates from plasma membrane to endosome, APP translocates from plasma membrane to endosome lumen

**Followed by:** Gamma-secretase cleaves APP(672-770) to APP(672-711) and APP(672-713)

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-05-12</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Gamma-secretase cleaves APP(672-770) to APP(672-711) and APP(672-713)

Location: Amyloid fiber formation

Stable identifier: R-HSA-9010096

Type: transition

Compartments: endosome membrane, endosome lumen

Beta secretase 1 (BACE1) catalyses the cleavage of APP(18-770) within the ectodomain and liberates a soluble proteolytic fragment, termed soluble APP beta (APPs beta, APP(18-671)) (Parvathy et al. 1999, Kinoshita et al. 2003). APPs beta is subsequently cleaved by the presenilin (PS) containing gamma secretase complex to eventually (step wise details of multiple cleavages not shown here) liberate the neurotoxic Abeta peptides 42 and 40 (APP(672 713) and APP(672 711) respectively) (Huse et al. 2002, Ehehalt et al. 2003, Anderson et al. 2005, Fukumori et al. 2006, Takami et al. 2009, Andrew et al. 2016).

Preceded by: BACE1 cleaves APP(18-770) to APP(18-671) and APP(672-770)

Followed by: APP(672-713),APP(672-711) translocate from endosome lumen to extracellular region

Literature references

APP(672-713), APP(672-711) translocate from endosome lumen to extracellular region

Location: Amyloid fiber formation

Stable identifier: R-HSA-6783332

Type: omitted

Compartments: extracellular region, endosome lumen

The Abeta peptides 42 and 40 (APP(672-713) and APP(673-711) respectively) are thought to be the main fibril-forming peptides implicated in neurodegenerative disorders. They translocate from the endosomal lumen to the extracellular region by an unknown mechanism (Qui et al. 2015, Baranello et al. 2015).

Preceded by: Gamma-secretase cleaves APP(672-770) to APP(672-711) and APP(672-713)

Followed by: Amyloid precursor proteins form ordered fibrils

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author/Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015-06-12</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2015-06-26</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>

https://reactome.org
The sortilin-related receptor (SORL1) is expressed mainly in brain, where it is most abundant in the cerebellum, cerebral cortex and the occipital pole. It acts as a sorting receptor that mediates anterograde and retrograde movement of APP between the trans-Golgi network and early endosomes, thereby restricting delivery of the APP precursor to endocytic compartments that favour amyloidogenic peptide production (Andersen et al. 2005, Willnow & Andersen 2013, Yin et al. 2015, Hermey 2015). Targeting SORL1 might present novel opportunities for Alzheimer's disease therapy.

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Author/Reviewer</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016-05-17</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2016-07-15</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
</tbody>
</table>
SORL1 transports APP(18-770) from endosome lumen to Golgi lumen

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-8871506

**Type:** transition

**Compartments:** endosome membrane, Golgi membrane

The sortilin-related receptor (SORL1) is expressed mainly in brain, where it is most abundant in the cerebellum, cerebral cortex and the occipital pole. It acts as a sorting receptor that mediates anterograde and retrograde movement of APP between the trans-Golgi network and early endosomes, thereby restricting delivery of the APP precursor to endocytic compartments that favour amyloidogenic peptide production (Andersen et al. 2005, Willnow & Andersen 2013, Yin et al. 2015, Hermey 2015). Targeting SORL1 might present novel opportunities for Alzheimer’s disease therapy.

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author/Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016-05-17</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2016-07-15</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
</tbody>
</table>
Amyloid precursor proteins form ordered fibrils

Location: Amyloid fiber formation

Stable identifier: R-HSA-977136

Type: transition

Compartments: extracellular region

Diseases: Amyloidosis

Amyloid fibril formation is associated with a wide range of diseases (Chiti & Dobson 2006), though the accumulation and deposition of fibrillar material does not correlate well with disease pathogenesis and it is now widely believed that oligomeric amyloid forms are largely responsible for the cytotoxic effects of amyloid (Glabe 2009). Fibrils have been described as more like crystalline polymer structures than the protein monomers they are derived from (Wetzel et al. 2007). In vitro, fibril formation is usually preceded by the association of monomers into oligomeric structures (Kodali & Wetzel 2007), though this remains to be established in vivo. Amyloid-beta forms spherical structures with around 12 units (Bernstein et al. 2005). Larger structures called protofibrils are also observed, non-spherical filamentous structures lacking a periodic substructure (Goldsbury 2005).

Preceded by: APP(672-713),APP(672-711) translocate from endosome lumen to extracellular region

Followed by: Amyloid fibrils have additional components

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010-10-15</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>

https://reactome.org
In addition to the main fibril peptide, mature amyloid fibrils have additional components. Serum amyloid P component (SAP) binds to all types of amyloid fibrils and is a universal constituent of amyloid deposits. SAP binding protects amyloid fibrils from proteolytic degradation (Tennent et al. 1995, Westermark 2005). SAP may function as a chaperone for amyloid formation (Coker et al. 2000).

Glycosaminoglycans (GAGs) and proteoglycans are found associated with all types of amyloid deposits (Alexandrescu 2005). Of the different types of GAG heparan sulfate and dermatan sulfate are the most prominent in amyloid deposits (Hirschfield & Hawkins, 2003). GAGs have been implicated in the nucleation of fibrils, they can also stabilize mature fibrils against dissociation (Yamaguchi et al. 2003) and proteolytic degradation (Gupta-Bansal et al. 1995).

Perlecan coimmunolocalizes with all types of amyloids (Snow & Wright 1989), accelerating fibril formation (Castillo et al. 1998), stabilizing them once formed (Castillo et al. 1997), and protecting them from proteolytic degradation (Gupta-Bansal et al. 1995).

APOE isoform 4 binds tightly to soluble ABeta peptide forming complexes that resist dissociation; it also binds to ABeta in its fibril form (Bales et al. 2002).

**Preceded by:** Amyloid precursor proteins form ordered fibrils, Serum amyloid P-component forms homopentamers

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010-10-15</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>

https://reactome.org
Formation of serum amyloid P decamer

Location: Amyloid fiber formation

Stable identifier: R-HSA-976817

Type: binding

Compartments: extracellular region

At physiological pH serum amyloid P component is a decamer of two pentameric rings lying face to face. This non-covalent interaction is readily dissociated by reducing the pH.

Preceded by: Serum amyloid P-component forms homopentamers

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010-10-15</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>
Serum amyloid P binds DNA and chromatin

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-977224

**Type:** binding

**Compartments:** extracellular region

Serum amyloid P component (SAP) binds DNA and chromatin in a calcium dependent manner in physiological conditions (Pepys et al. 1987). This binding displaces H1-type histones (Butler et al. 1990), solubilizing chromatin which is otherwise insoluble in extracellular fluids. SAP may therefore participate in the in vivo handling of chromatin exposed by cell death. SAP knockout mice spontaneously develop antinuclear autoimmunity and severe glomerulonephritis, a phenotype resembling human systemic lupus erythematosus, a serious autoimmune disease, suggesting that SAP binding may play a role in reducing the immunogenicity of chromatin and preventing autoimmunity (Bickerstaff et al. 1999).

**Preceded by:** Serum amyloid P-component forms homopentamers

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010-10-15</td>
<td>Authored</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Edited</td>
<td>Jupe, S.</td>
</tr>
<tr>
<td>2011-04-08</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
<tr>
<td>2015-11-09</td>
<td>Reviewed</td>
<td>Perry, G.</td>
</tr>
</tbody>
</table>

[https://reactome.org](https://reactome.org)
CALB1 binds $4\times \text{Ca}^{2+}$

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-8932599

**Type:** binding

**Compartments:** cytosol

Calbindin (CALB1, aka D-28K, CAB27) is a calcium binding protein with six EF hand domains, functions as both a calcium buffer and a sensor protein and plays a vital role in neurological function. CALB1 binds four calcium ions at its four functional calcium-binding sites (EF hands 1, 3, 4 and 5), subsequently undergoing a conformational change. EF hands 2 and 6 are known not to bind calcium (Kojetin et al. 2006, Hobbs et al. 2009). Cholinergic neurons of the basal forebrain (BFCN) are selectively vulnerable in Alzheimer's disease (AD). Most of the BFCN in the human brain contain CALB1 and a large proportion lose their CALB1 in the course of normal aging. The BFCN which degenerate in AD lack CALB1, depriving neurons of the capacity to buffer high levels of intracellular calcium and thus leaving them vulnerable to pathological processes, such as those in AD, which can cause increased intracellular calcium, leading to their degeneration (Geula et al. 2003, Ahmadian et al. 2015).

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Author/Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016-07-27</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2016-08-12</td>
<td>Reviewed</td>
<td>D'Eustachio, P.</td>
</tr>
</tbody>
</table>

[https://reactome.org](https://reactome.org)
ADAM10:Zn2+ binds TSPANs

Location: Amyloid fiber formation

Stable identifier: R-HSA-9010113

Type: binding

Compartments: endoplasmic reticulum lumen

The ADAM (A disintegrin and metalloprotease domain) family are membrane-anchored metalloproteases that mediate the proteolytic cleavage of many transmembrane proteins within their extracellular regions. This so-called ectodomain shedding plays an important role in many cell and developmental processes. ADAM10 (A Disintegrin and Metalloproteinase 10) has been identified as the major physiological alpha-secretase in neurons (Lammich et al. 1999, Kuhn et al. 2010), responsible for cleaving amyloid precursor protein (APP) in a non-amyloidogenic manner and producing APPs-alpha, a neuroprotective APP-derived peptide.

The trafficking of ADAM10 is regulated by a subgroup of the tetraspanin superfamily which have eight cysteines in the largest of the two extracellular domains and are referred to as TspanC8 tetraspanins. Tetraspanins associate specifically and directly with a limited number of proteins, and also with other tetraspanins, thereby generating a "tetraspanin web". Through these interactions, tetraspanins are believed to have a role in cell and membrane compartmentalisation (Charrin et al. 2014). TSPAN4, 14, 15 and 33 are thought to mediate ADAM10 exit from the ER and transport to the plasma membrane in a variety of ways (Noy et al. 2016, Jouannet et al. 2016).

Followed by: ADAM10:Zn2+:TSPANs translocates from ER lumen to plasma membrane

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author/Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017-06-26</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2018-08-10</td>
<td>Reviewed</td>
<td>Meras-Rios, A.</td>
</tr>
</tbody>
</table>
ADAM10:Zn2+:TSPANs translocates from ER lumen to plasma membrane

Location: Amyloid fiber formation

Stable identifier: R-HSA-9010074

Type: omitted

Compartments: plasma membrane, endoplasmic reticulum lumen

The ADAM (A disintegrin and metalloprotease domain) family are membrane-anchored metalloproteases that mediate the proteolytic cleavage of many transmembrane proteins within their extracellular regions. This so-called ectodomain shedding plays an important role in many cell and developmental processes. ADAM10 (A Disintegrin and Metalloproteinase 10) has been identified as the major physiological alpha-secretase in neurons (Lammich et al. 1999, Kuhn et al. 2010), responsible for cleaving amyloid precursor protein (APP) in a non-amyloidogenic manner and producing APPs-alpha, a neuroprotective APP-derived peptide.

The trafficking of ADAM10 is regulated by a subgroup of the tetraspanin superfamily referred to as TspanC8 tetraspanins. TSPAN4, 14, 15 and 33 are thought to mediate ADAM10 exit from the ER and transport to the plasma membrane in a variety of ways (Noy et al. 2016, Jouannet et al. 2016).

Preceded by: ADAM10:Zn2+ binds TSPANs

Literature references


Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Author/Editor</th>
<th>Reviewed By</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017-06-26</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2018-08-10</td>
<td>Reviewed</td>
<td>Meras-Rios, A.</td>
</tr>
</tbody>
</table>
ADAM10 (A Disintegrin and Metalloproteinase 10) has been identified as the major physiological alpha-secretase in neurons (Lammich et al. 1999, Kuhn et al. 2010), responsible for cleaving amyloid precursor protein (APP(18-770)) in a non-amyloidogenic manner and producing APPs-alpha (APP(18-687), a neuroprotective APP-derived peptide (Mockett et al. 2017, Endres & Deller 2017). This cleavage also produces a cellular fragment, C83/CTF-alpha (APP(688-770)). Cleavage by alpha-secretase at the cell surface is the major pathway in APP processing, accounting for 80–90% of APP turnover.

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author/Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017-06-26</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2018-08-10</td>
<td>Reviewed</td>
<td>Meras-Rios, A.</td>
</tr>
</tbody>
</table>
APP translocates from plasma membrane to endosome lumen

**Location:** Amyloid fiber formation

**Stable identifier:** R-HSA-9010091

**Type:** omitted

**Compartments:** plasma membrane, endosome lumen

APP that does not get processed by alpha-secretase in the non-amyloidogenic pathway is internalised to endosomes for further processing (Baranello et al. 2015).

**Followed by:** BACE1 cleaves APP(18-770) to APP(18-671) and APP(672-770)

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author/Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017-06-26</td>
<td>Authored, Edited</td>
<td>Jassal, B.</td>
</tr>
<tr>
<td>2018-08-10</td>
<td>Reviewed</td>
<td>Meras-Rios, A.</td>
</tr>
</tbody>
</table>
# Table of Contents

## Introduction

- Amyloid fiber formation
  - SIAH1, SIAH2 bind SNCAIP
  - SIAH1, SIAH2 ubiquitinate SNCAIP
  - PARK2 binds SNCAIP
  - PARK2 K63-Ubiquitinates SNCAIP
  - SIAH1:UBE2L6:Ubiquitin binds SNCA
  - SIAH1:UBE2L6:Ubiquitin ubiquitinates SNCA
  - Ub-SNCA dissociates from the conjugating enzyme
  - USP9X binds Ub-SNCA
  - USP9X deubiquitinates Ub-SNCA
  - SNCAIP binds alpha-synuclein
  - Serum amyloid P-component forms homopentamers
  - NAT8,8B acetylate BACE1
  - BACE1 translocates from ER lumen to Golgi apparatus
  - FURIN cleaves 7K-BACE1 to 7K-BACE1(46-501)
  - Unknown deacetylase deacetylates 7K-BACE1(46-501)
  - BACE1(46-501) translocates from Golgi lumen to plasma membrane
  - BACE1 binds GGA1,2,3
  - BACE1:GGA1,2,3 translocates from plasma membrane to endosome
  - BACE1 cleaves APP(18-770) to APP(18-671) and APP(672-770)
  - Gamma-secretase cleaves APP(672-770) to APP(672-711) and APP(672-713)
  - APP(672-713),APP(672-711) translocate from endosome lumen to extracellular region
  - SORL1 binds APP(18-770)
  - SORL1 transports APP(18-770) from endosome lumen to Golgi lumen
  - Amyloid precursor proteins form ordered fibrils
  - Amyloid fibrils have additional components
  - Formation of serum amyloid P decamer
  - Serum amyloid P binds DNA and chromatin
  - CALB1 binds 4xCa2+
  - ADAM10:Zn2+ binds TSPANs
  - ADAM10:Zn2+:TSPANs translocates from ER lumen to plasma membrane
  - ADAM10:Zn2+:TSPANs cleaves APP(18-770)
APP translocates from plasma membrane to endosome lumen

Table of Contents